Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: Issues and challenges

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL. 5, 2012, Pages 64-69

  Poljak, M ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cervical cancer; Human papillomaviruses; Vaccination

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HEALTH CARE PLANNING; HUMAN; LONG TERM CARE; LOWEST INCOME GROUP; NONHUMAN; OROPHARYNX CANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 84867403250     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03946.x     Document Type: Review

References (43)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-79.
2. Bouvard V, Baan R, Straif K et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10: 321-322.
3. Arbyn M, Castellsagué X, de Sanjosé S et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686.
4. Brotherton JM, Gertig DM. Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact. Expert Rev Anti Infect Ther 2011; 9: 627-639.
5. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113: 3036-3046.
6. Chaturvedi AK, Engels EA, Pfeiffer RM et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
7. FUTURE Study Group II. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
8. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. FUTURE I Investigators. N Engl J Med 2007; 356: 1928-1943.
9. Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-1702.
10. Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364: 401-411.
11. Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009; 374: 301-314.
12. Palefsky JM, Giuliano AR, Goldstone S et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-1585.
13. Wheeler CM, Castellsagué X, Garland SM et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-110.
14. Lehtinen M, Paavonen J, Wheeler CM et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
15. Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine Gardasil. J Adolesc Health 2011; 49: 467-475.
16. Donovan B, Franklin N, Guy R et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11: 39-44.
17. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87: 544-547.
18. Brotherton JML, Fridman M, May C, Chappell G, Saville AM, Gertig DM. Early impact of the HPV vaccination program on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-2092.
19. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs 2010; 70: 1079-1098.
20. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infect Dis 2011; 11: 13. doi: 10.1002/ijc.26362. [Epub ahead of print].
21. Garnock-Jones KP, Giuliano AR. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males. Drugs 2011; 71: 591-602.
22. McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011; 71: 465-488.
23. Szarewski A. HPV vaccine: Cervarix. Expert Opin Biol Ther 2010; 10: 477-487.
24. Kane MA. Preventing cancer with vaccines: progress in the global control of cancer. Cancer Prev Res (Phila) 2012; 5: 24-29.
25. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200: 166-171.
26. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 2011; 85: 13253-13259.
27. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) 2012; 5: 18-23.
28. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26years. J Infect Dis 2009; 199: 926-935.
29. Romanowski B, de Borba PC, Naud PS et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4years. Lancet 2009; 374: 1975-1985.
30. Dillner J, Arbyn M, Unger E, Dillner L. Monitoring of human papillomavirus vaccination. Clin Exp Immunol 2011; 163: 17-25.
31. Mendoza N, Hernandez PO, Tyring SK. HPV vaccine update: new indications and controversies. Skin Therapy Lett 2011; 16: 1-3.
32. Schiffman M, Wacholder S. Success of HPV vaccination is now a matter of coverage. Lancet Oncol 2012; 13: 10-12.
33. Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009; 27: 7270-7281.
34. Garland SM. Human papillomavirus vaccination: where to now? Sex Transm Infect 2011; 87 (Suppl 2): ii23-ii24.
35. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010; 28: 4731-4737.
36. World Health Organization. Meeting of the WHO Human Papillomavirus Vaccine Advisory Committee, April 2010. Weekly Epidemiol Rec 2011; 22: 227-231.
37. Brabin L, Kitchener HC, Stern PL. Implementation of prophylactic HPV vaccination: progress and future challenges. Expert Rev Obstet Gynecol 2010; 5: 591-603.
38. Poljak M, Kocjan BJ. Commercially available tests for multiplex detection of alpha human papillomaviruses. Exp Rev Anti Infect Ther 2010; 8: 1139-1162.
39. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60: 1705-1708.
40. Committee on Infectious Diseases. HPV vaccine recommendations. Pediatrics 2012; 129: 602-605.
41. Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sex Health 2010; 7: 352-358.
42. Kreimer AR, Rodriguez AC, Hildesheim A et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103: 1444-1451.
43. Romanowski B, Schwarz TF, Ferguson LM et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7: 1374-1386.